Clinical Trials

200 enrolled 27 charts

Breast Neoplasms

NCT04030455 2026-03-09

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

28 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms

NCT00707473 2026-03-05

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

31 enrolled

Sinonasal undifferentiated carcinoma, Paranasal Sinus Neoplasms

NCT04522336 2026-03-05

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

16 enrolled

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8

NCT03574571 2026-02-27

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

732 enrolled

Prostatic Neoplasms

NCT07421141 2026-02-27

Opti-HER2

186 enrolled

Breast Neoplasms

NCT03611738 2026-02-09

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

21 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04884282 2026-02-06

COMBI-TED

105 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03598595 2026-02-04

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

31 enrolled

Sarcoma

Osteosarcoma

NCT05616624 2026-02-04

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Phase 1/2 Active not recruiting

31 enrolled

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT04340882 2026-01-30

DoceRamPem

30 enrolled

Lung Neoplasms

NCT05500092 2026-01-28

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

17 enrolled

Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

NCT03246347 2026-01-23

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

40 enrolled 12 charts

Prostatic Neoplasms

NCT04126070 2026-01-22

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

60 enrolled

Hormone Sensitive Prostate Cancer

NCT03456843 2026-01-21

Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

190 enrolled

Stage IV Prostate Adenocarcinoma AJCC v7

NCT03879577 2026-01-21

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

53 enrolled 13 charts

Breast Neoplasms

NCT06734130 2026-01-21

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

25 enrolled

Prostatic Neoplasms

NCT04872985 2026-01-06

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

140 enrolled

Breast Neoplasms

NCT04367311 2026-01-02

Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

100 enrolled

Lung Neoplasms

NCT01154920 2025-12-17

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

128 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

32 enrolled

Prostatic Neoplasms

NCT04193059 2025-11-26

PANSY

1,560 enrolled

Breast Neoplasms

NCT04386746 2025-11-17

GEMDOCE

27 enrolled 9 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03582475 2025-11-12

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

15 enrolled 17 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Prostatic Neoplasms, Urethral Neoplasms

NCT02495896 2025-11-10

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

GastrointestinalHead & NeckThoracic

61 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Pancreatic Neoplasms

NCT05252429 2025-09-12

Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma

27 enrolled

Head and Neck Neoplasms

NCT04015622 2025-08-20

PROTRACT

100 enrolled

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT03421288 2025-07-25

DANTE

677 enrolled

Stomach Neoplasms

NCT04343885 2025-07-11

UpFrontPSMA

130 enrolled

Metastatic Hormone Naive Prostate Cancer

NCT00076310 2025-06-26

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

50 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT02913196 2025-05-23

Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC

16 enrolled

Prostate Cancer Metastatic

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

423 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT03161353 2025-04-23

PHERGain

377 enrolled

Breast Neoplasms

NCT02547987 2025-03-12

CADENCE

25 enrolled 9 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05599789 2025-02-18

KeyPemls-004

47 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Breast Neoplasms

NCT00798070 2024-12-18

PANTHER

2,017 enrolled

Breast Neoplasms, Neoplasms

NCT04745988 2024-11-15

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer

43 enrolled

Stomach Neoplasms

NCT01957436 2024-11-12

PEACE1

1,173 enrolled

Neoplasms, Prostatic Neoplasms

NCT04723875 2024-11-01

Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline

Phase 2/3 Active not recruiting

306 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

136 enrolled

HER2-positive Breast Cancer

NCT03230734 2024-09-27

RAPSON

70 enrolled

Prostatic Neoplasms

NCT04158440 2024-07-09

Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

501 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05816499 2024-06-17

AK104IIT018

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

271 enrolled

Breast Neoplasms

NCT02509286 2024-05-08

ESOPEC

438 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms

NCT03833440 2024-05-03

PIONeeR

114 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02931890 2024-05-02

CRITICS-II

207 enrolled

Stomach Neoplasms

NCT03700099 2024-04-15

Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide

30 enrolled